Pediatrix Medical Group, Inc.

NYSE:MD Stock Report

Market Cap: US$897.5m

Pediatrix Medical Group Future Growth

Future criteria checks 3/6

Pediatrix Medical Group is forecast to grow earnings and revenue by 97.4% and 0.3% per annum respectively. EPS is expected to grow by 97.2% per annum. Return on equity is forecast to be 14.3% in 3 years.

Key information

97.4%

Earnings growth rate

97.2%

EPS growth rate

Healthcare earnings growth19.3%
Revenue growth rate0.3%
Future return on equity14.3%
Analyst coverage

Good

Last updated03 Sep 2024

Recent future growth updates

Recent updates

Improved Revenues Required Before Pediatrix Medical Group, Inc. (NYSE:MD) Stock's 32% Jump Looks Justified

Aug 07
Improved Revenues Required Before Pediatrix Medical Group, Inc. (NYSE:MD) Stock's 32% Jump Looks Justified

Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?

Jun 19
Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?

Pediatrix Medical Group (NYSE:MD) Has Some Way To Go To Become A Multi-Bagger

May 10
Pediatrix Medical Group (NYSE:MD) Has Some Way To Go To Become A Multi-Bagger

Pediatrix Medical Group, Inc.'s (NYSE:MD) Price Is Right But Growth Is Lacking

Mar 29
Pediatrix Medical Group, Inc.'s (NYSE:MD) Price Is Right But Growth Is Lacking

Pediatrix Medical Group, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 100% Above Its Share Price

Jan 10
Pediatrix Medical Group, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 100% Above Its Share Price

Pediatrix Medical Group, Inc.'s (NYSE:MD) Earnings Are Not Doing Enough For Some Investors

Dec 25
Pediatrix Medical Group, Inc.'s (NYSE:MD) Earnings Are Not Doing Enough For Some Investors

Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?

Nov 14
Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?

Is It Time To Consider Buying Pediatrix Medical Group, Inc. (NYSE:MD)?

Oct 13
Is It Time To Consider Buying Pediatrix Medical Group, Inc. (NYSE:MD)?

Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?

Aug 09
Does Pediatrix Medical Group (NYSE:MD) Have A Healthy Balance Sheet?

Pediatrix: Unable To Deploy Capital Tied Up In Cash Conversion Cycle, Reiterate Hold

Aug 08

At US$14.21, Is Pediatrix Medical Group, Inc. (NYSE:MD) Worth Looking At Closely?

Jul 03
At US$14.21, Is Pediatrix Medical Group, Inc. (NYSE:MD) Worth Looking At Closely?

The Returns At Pediatrix Medical Group (NYSE:MD) Aren't Growing

Jun 08
The Returns At Pediatrix Medical Group (NYSE:MD) Aren't Growing

Pediatrix Medical Group (NYSE:MD) Has A Somewhat Strained Balance Sheet

Apr 26
Pediatrix Medical Group (NYSE:MD) Has A Somewhat Strained Balance Sheet

Is Now An Opportune Moment To Examine Pediatrix Medical Group, Inc. (NYSE:MD)?

Feb 20
Is Now An Opportune Moment To Examine Pediatrix Medical Group, Inc. (NYSE:MD)?

Pediatrix Medical Group Q4 2022 Earnings Preview

Feb 16

Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?

Jan 12
Is Pediatrix Medical Group (NYSE:MD) A Risky Investment?

Pediatrix: RCM Overhang Now Too Heavy, Revise To Hold

Dec 22

Return Trends At Pediatrix Medical Group (NYSE:MD) Aren't Appealing

Dec 20
Return Trends At Pediatrix Medical Group (NYSE:MD) Aren't Appealing

Pediatrix appoints James Swift as chief executive officer

Dec 15

Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching

Nov 05
Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching

Pediatrix Medical Group GAAP EPS of $0.37 misses by $0.11, revenue of $489.92M misses by $21.54M

Nov 03

Pediatrix: These 5 Graphs Suggest It's A Buy

Sep 29

Here's Why Pediatrix Medical Group (NYSE:MD) Can Manage Its Debt Responsibly

Sep 13
Here's Why Pediatrix Medical Group (NYSE:MD) Can Manage Its Debt Responsibly

Here's What To Make Of Pediatrix Medical Group's (NYSE:MD) Decelerating Rates Of Return

Aug 29
Here's What To Make Of Pediatrix Medical Group's (NYSE:MD) Decelerating Rates Of Return

Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching

Jul 27
Why Pediatrix Medical Group, Inc. (NYSE:MD) Could Be Worth Watching

Pediatrix: Seeking 46% Return Objective As Speculative Buy

Jul 14

MEDNAX, Inc. (NYSE:MD) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jun 24
MEDNAX, Inc. (NYSE:MD) Shares Could Be 47% Below Their Intrinsic Value Estimate

MEDNAX (NYSE:MD) Has A Pretty Healthy Balance Sheet

May 25
MEDNAX (NYSE:MD) Has A Pretty Healthy Balance Sheet

Return Trends At MEDNAX (NYSE:MD) Aren't Appealing

Apr 20
Return Trends At MEDNAX (NYSE:MD) Aren't Appealing

MEDNAX, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 96% Above Its Share Price

Mar 08
MEDNAX, Inc.'s (NYSE:MD) Intrinsic Value Is Potentially 96% Above Its Share Price

MEDNAX (NYSE:MD) Seems To Use Debt Quite Sensibly

Feb 15
MEDNAX (NYSE:MD) Seems To Use Debt Quite Sensibly

Here's What's Concerning About MEDNAX's (NYSE:MD) Returns On Capital

Jan 19
Here's What's Concerning About MEDNAX's (NYSE:MD) Returns On Capital

Is MEDNAX, Inc. (NYSE:MD) Trading At A 40% Discount?

Nov 17
Is MEDNAX, Inc. (NYSE:MD) Trading At A 40% Discount?

These 4 Measures Indicate That MEDNAX (NYSE:MD) Is Using Debt Reasonably Well

Oct 23
These 4 Measures Indicate That MEDNAX (NYSE:MD) Is Using Debt Reasonably Well

Here's What's Concerning About MEDNAX's (NYSE:MD) Returns On Capital

Oct 08
Here's What's Concerning About MEDNAX's (NYSE:MD) Returns On Capital

Earnings and Revenue Growth Forecasts

NYSE:MD - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,99796N/AN/A4
12/31/20251,982961081327
12/31/20241,998-141041227
6/30/20242,002-252100131N/A
3/31/20241,999-7181113N/A
12/31/20231,995-60104137N/A
9/30/20232,01288133167N/A
6/30/20231,99595139170N/A
3/31/20231,98198134164N/A
12/31/20221,97263137167N/A
9/30/20221,9577989112N/A
6/30/20221,960826390N/A
3/31/20221,947823161N/A
12/31/20211,9111084477N/A
9/30/20211,82972-1521N/A
6/30/20211,7973899129N/A
3/31/20211,73914236264N/A
12/31/20201,734-10176205N/A
9/30/20201,776-4326352N/A
6/30/20201,77011321341N/A
3/31/20201,6781261284N/A
12/31/20191,78042338358N/A
9/30/20192,21094331351N/A
6/30/20192,603143292320N/A
3/31/20193,145221296324N/A
12/31/20181,723122297314N/A
9/30/20183,477333303346N/A
6/30/20183,497337371417N/A
3/31/20183,475326N/A420N/A
12/31/20173,253305N/A498N/A
9/30/20173,378262N/A447N/A
6/30/20173,337293N/A443N/A
3/31/20173,266312N/A455N/A
12/31/20163,183325N/A444N/A
9/30/20163,094340N/A417N/A
6/30/20162,988334N/A393N/A
3/31/20162,893336N/A389N/A
12/31/20152,780336N/A369N/A
9/30/20152,689332N/A443N/A
6/30/20152,593327N/A431N/A
3/31/20152,512322N/A419N/A
12/31/20142,439317N/A423N/A
9/30/20142,356308N/A383N/A
6/30/20142,284299N/A382N/A
3/31/20142,218289N/A374N/A
12/31/20132,154281N/A405N/A
9/30/20132,058268N/A371N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).

Earnings vs Market: MD is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MD is expected to become profitable in the next 3 years.

Revenue vs Market: MD's revenue (0.3% per year) is forecast to grow slower than the US market (8.7% per year).

High Growth Revenue: MD's revenue (0.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MD's Return on Equity is forecast to be low in 3 years time (14.3%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y